SCHEMBL361958

SCHEMBL361958

C=C(C)C(=O)OCc1ccc2c3c(ccc2c1)OC(c1ccccc1)(c1ccccc1)C=C3

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.32
KDM4E B2RXH2 1/20 0.32
MEN1 O00255 1/20 0.32
NPC1 O15118 1/20 0.32
LMNA P02545 1/20 0.32
GLA P06280 1/20 0.32
GAA P10253 1/20 0.32
MAPT P10636 1/20 0.32
HPGD P15428 1/20 0.32
KMT2A Q03164 1/20 0.32
CYP3A4 P08684 1/20 0.32
HIF1A Q16665 2/20 0.32
HTT P42858 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
SLC1A3 P43003 1/20 0.32
SLC1A2 P43004 1/20 0.32
SLC1A1 P43005 1/20 0.32
EDNRA P25101 1/20 0.32
GSTA2 P09210 1/20 0.30
GSTP1 P09211 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10026214 0.86 ALDH1A1 (0.32) ALDH1A1NPC1MAPTHIF1ASMN1; SMN2
SCHEMBL15157836 0.80 HTT (0.41) ALDH1A1KDM4EMEN1NPC1LMNA
SCHEMBL364008 0.79 KDM4E (0.34) ALDH1A1KDM4EMEN1NPC1LMNA
SCHEMBL13171565 0.75 CA2 (0.41) ALDH1A1KDM4ENPC1LMNAMAPT
SCHEMBL29503697 0.71 TACR1 (0.47) ALDH1A1SLC1A3SLC1A2SLC1A1CACNA1B
SCHEMBL2619047 0.71 TACR1 (0.47) ALDH1A1SLC1A3SLC1A2SLC1A1CACNA1B
SCHEMBL1324374 0.71 CA2 (0.43) ALDH1A1KDM4ENPC1LMNAMAPT
SCHEMBL25106661 0.70 GPR84 (0.39) ALDH1A1KDM4EMEN1NPC1LMNA
SCHEMBL15157837 0.70 ATM (0.35) ALDH1A1KDM4EMEN1NPC1MAPT
SCHEMBL15020074 0.70 TACR1 (0.43) ALDH1A1SLC1A3SLC1A2SLC1A1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8500807-B2 Photochromic intraocular lens CARL ZEISS MEDITEC SAS (FR) 2013-08-06 US disclosed
US-8500807-B2 Photochromic intraocular lens CARL ZEISS MEDITEC SAS (FR) 2013-08-06 US disclosed
EP-1753838-B1 POLYMERISABLE NAPHTHOPYRAN DERIVATIVES AND POLYMER MATERIALS OBTAINED FROM SAID DERIVATIVES POLYMEREXPERT S A (FR) 2012-03-14 EP disclosed
US-20100317805-A1 POLYMERISABLE NAPHTHOPYRANE DERIVATIVES AND POLYMER MATERIALS OBTAINED FROM THESE DERIVATIVES POLYMEREXPERT (FR) 2010-12-16 US disclosed
US-20100317805-A1 POLYMERISABLE NAPHTHOPYRANE DERIVATIVES AND POLYMER MATERIALS OBTAINED FROM THESE DERIVATIVES POLYMEREXPERT (FR) 2010-12-16 US disclosed
US-20080200983-A1 Photochromic Intraocular Lens IOLTECHNOLOGIE-PRODUCTION (FR) 2008-08-21 US disclosed
US-20080200983-A1 Photochromic Intraocular Lens IOLTECHNOLOGIE-PRODUCTION (FR) 2008-08-21 US disclosed
US-20070197750-A1 Polymerisable naphthopyrane derivatives and polymer materials obtained from these derivatives POLYMEREXPERT (FR) 2007-08-23 US disclosed
US-20070197750-A1 Polymerisable naphthopyrane derivatives and polymer materials obtained from these derivatives POLYMEREXPERT (FR) 2007-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197750-A1 Polymerisable naphthopyrane derivatives and polymer materials obtained from these derivatives CCND3, H1-3, H1-0 ALDH1A1 1397/4885KDM4E 2000/4885MEN1 2826/4885
US-20100317805-A1 POLYMERISABLE NAPHTHOPYRANE DERIVATIVES AND POLYMER MATERIALS OBTAINED FROM THESE DERIVATIVES C1S, H1-0, H1-3 ALDH1A1 1029/4885KDM4E 3155/4885MEN1 1443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.